Click on image to view larger version.
FIGURE 5. (Top) Kaplan-Meier plots obtained in DCM patients with dipyridamole MBF of >1.36 mL·min–1·g–1 irrespective of New York Heart Association (NYHA) class (A) and in patients with dipyridamole MBF of 
1.36 mL·min–1·g–1 subdivided according to absence (NYHA class I) (B) or presence (NYHA classes II and III) (C) of heart failure symptoms at enrollment. (Bottom) Kaplan-Meier plots obtained in patients with dipyridamole MBF of >1.36 mL·min–1·g–1 irrespective of left ventricular end-diastolic dimension (A) and in patients with dipyridamole MBF of 1.36 mL·min–1·g–1 subdivided according to left ventricular end-diastolic dimension of 60 mm (B) or >60 mm (C) at enrollment. (Reprinted with permission of (190).)
